Exalenz Bioscience Ltd. reported earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company’s revenue increased 25% to $3.2 million compared to $2.5 million in the third quarter of 2017. The increase in revenue was primarily driven by penetration of the lab market in the U.S. Operating loss was $1.1 million in the third quarter 2018, compared to an operating loss of $1.1 million in the third quarter 2017. Adjusted EBITDA loss for the third quarter was $0.5 million, compared to $1.0 million in the third quarter 2017. Net loss amounted to $1.1 million in the third quarter 2018, similar to the net loss in the third quarter 2017, or $0.04 per basic and diluted share in both periods. For the nine months, the company’s revenue increased 50% to $9.8 million, compared to $6.5 million during the same period of 2017. The increase in revenue was primarily driven by penetration of the lab market in the U.S. Operating loss for the nine months ended September 30, 2018 was $3.4 million, compared to an operating loss of $3.8 million in the same period in 2017. Net loss for the nine months ended September 30, 2018 was $3.1 million, or $0.12 per basic and diluted share, compared to $4.1 million, or $0.16 per basic and diluted share, for the nine months ended September 30, 2017.